Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeuticsâ portfolio of technologies utilizes three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Given the limited capacity of the human heart for self-regeneration, Kardiaâs technologies have the potential to offer significantly improved patient outcomes compared to existing treatment
